世界首款阿尔茨海默症药被证有效?外媒:还不能高兴太早
Drug company Biogen said on Tuesday that it would ask the Food and Drug Administration to approve an experimental drug, aducanumab, to treat people with mild cognitive impairment and the earliest signs of Alzheimer's disease. Alzheimer:['ælz'ɛmɚ]n. 阿尔茨海默症
Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation and language.
接受药物治疗的患者“在认知功能,如记忆力、定向能力和语言能力等方面,都得到了显著的改善。”
BBC:首款可以减缓阿尔茨海默症痴呆症状的药物
英国广播公司(BBC)报道指出,这一消息多少有些令人感到意外。
早在今年3月,百健和卫材公司曾宣布,将终止对“aducanumab”药物的两项后期试验,因为当时一项分析显示,他们成功研制出治疗阿尔茨海默综合症药物的希望十分渺茫。当时,这两家公司的股价一路大跌。
The announcement is somewhat surprising because the company had discontinued work on the drug in March 2019, after disappointing trial results.
不过,该公司称,新的数据显示,加大剂量对于治疗阿尔茨海默症早期症状,有显著效果,可以减缓患者记忆力衰退、遗忘日常生活技能等症状。
But the company says a new analysis of a larger dataset of the same studies shows that higher doses of aducanumab can provide a significant benefit to patients with early Alzheimer's, slowing their clinical decline so they preserve more of their memory and every day living skills - things that the disease usually robs.
根据最新试验分析,该公司“复活”了aducanumab。
The company resurrected the drug after additional analyses suggested it might have some effect at higher doses.
百健此次宣布药物的消息令市场十分兴奋。据报道,22日,百健公司的股票价格飙升27%,卫材公司的股价上涨了18%。几乎收回了3月份放弃这两项研究时的损失。
The drugmaker's shares soared 27% in New York trading, recouping almost all of the $18 billion it lost when it said in March it was abandoning the two studies. Shares in Eisai Co, Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading. 这家制药公司的股价在纽约市场上飙升了27%,几乎收回了3月份宣布放弃这两项研究时损失的180亿美元。百健公司的日本合作伙伴卫材的股票在东京市场中上涨了18%,达到6534日元的日最高限额。
对于这一消息,《纽约时报》直言,不能高兴太早(it is not quite time for these patients to celebrate)。
文章指出,该公司还没有公布最新分析数据,效果究竟如何还不得而知。目前看,只是能延缓阿尔茨海默症患者的一些认知衰退症状。
The company has not published the most recent analyses, and experts are mostly in the dark as to how well the drug works. It neither prevents nor cures Alzheimer's; the company claims only that aducanumab may slow cognitive decline in some patients.
该公司尚未公布最新分析数据,专家们大多数并不知道该药物效果如何。它不是预防或治愈阿尔茨海默症。公司只是说aducanumab可能会延缓某些患者的认知衰退症状。
Credit Suisse analyst Fumiyoshi Sakai said the new datasets would be presented at clinical trials meetings in early December. FDA approval was not guaranteed, and investors and analysts would remain cautious until we see a real product, he said.
瑞士信贷分析师Fumiyoshi Sakai表示,新数据将在12月初的临床试验会议上公布。他说,FDA的批准尚无保证,在看到真正的产品之前,投资者和分析师应保持谨慎。
▌如果药物有效,将成为一个新纪元的开端
加利福尼亚大学阿尔茨海默症研究者Michael Weiner博士说,如果成功了,该药物将成为一场胜利,“拉开新纪元的序幕。”
If it succeeds, the drug would be a triumph, “the dawn of a new era,” said Dr. Michael Weiner, an Alzheimer's researcher at the University of California, San Francisco.
他强调说,“当然,只是减缓症状,不是治愈。对患者的实际影响,还有待观察。”
Still, “this is not a cure,” he added. “It is a slowing of decline. The practical impact on patients remains to be seen.”
▌全球约有5000万阿尔茨海默综合症患者
影视剧《都挺好》中苏大强属于阿尔茨海默症患者
编辑:唐晓敏
实习生:赖暘 王丽
来源:中新网 路透社 CNBC 虎嗅网 纽约时报 BBC等
China Daily热词训练营上线啦!
点击图片,了解更多↓↓↓
推 荐 阅 读
中国驻英大使馆:英警方称尚无法确定货车39名遇难者为中国国籍
中国日报双语新闻
↑长按关注中国最大的双语资讯公众号↑